.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Dow
Harvard Business School
Queensland Health
Cerilliant
Baxter
Covington
Mallinckrodt
Argus Health
Deloitte

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,858,584

« Back to Dashboard

Which drugs does patent 6,858,584 protect, and when does it expire?


Patent 6,858,584 protects VIBATIV and is included in one NDA.

This patent has eighty-eight patent family members in thirty-four countries.

Summary for Patent: 6,858,584

Title: Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Abstract:Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
Inventor(s): Judice; J. Kevin (El Granada, CA), Shaw; Jeng-Pyng (Saratoga, CA), Mu; YongQi (Los Altos, CA), Conner; Michael W. (Half Moon Bay, CA), Pace; John L. (San Anselma, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:09/846,893
Patent Claim Types:
see list of patent claims
Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Theravance BiopharmaVIBATIVtelavancin hydrochloridePOWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY► Subscribe
Theravance BiopharmaVIBATIVtelavancin hydrochloridePOWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,858,584

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,691Glycopeptide phosphonate derivatives► Subscribe
7,244,705Polyacid glycopeptide derivatives► Subscribe
6,872,804 Glycopeptide disulfide and thioester derivatives► Subscribe
7,700,550Glycopeptide phosphonate derivatives► Subscribe
7,157,554Glycopeptide carboxy-saccharide derivatives► Subscribe
7,026,288Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin► Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives► Subscribe
8,158,580Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin► Subscribe
8,859,506Glycopeptide phosphonate derivatives► Subscribe
6,887,976 Glycopeptide phosphonate derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,858,584

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine75083► Subscribe
TaiwanI305209► Subscribe
Slovakia287470► Subscribe
Slovakia18522002► Subscribe
Slovenia1292612► Subscribe
Slovenia1278549► Subscribe
Slovenia1276759► Subscribe
Serbia50499► Subscribe
Yugoslavia96902► Subscribe
Portugal1292612► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Citi
Argus Health
Cantor Fitzgerald
US Department of Justice
Queensland Health
Moodys
Fish and Richardson
Chinese Patent Office
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot